Oncol Res Treat. 2017;40(6):342-346. doi: 10.1159/000477254. Epub 2017 May 17.
The treatment of head and neck squamous cell carcinoma (HNSCC) has been a medical challenge with limited improvement in overall survival over the past few decades. However, recently, very interesting innovations in the field of immunotherapy have been shown to be beneficial for patients with advanced HNSCC. In this article, the latest medical developments are reviewed with special focus on the clinical achievements and current clinical studies in the field of immunotherapy. The landscape of clinical studies has changed considerably from antibody-based growth factor inhibition towards immune checkpoint modulation, and new indications in the adjuvant and neoadjuvant setting are being tested in large patient cohorts. Even the combination of 2 or more immune modulatory approaches and the correct synchronization with standard cancer therapy is promising and warrants suitable clinical trials.
头颈部鳞状细胞癌（HNSCC）的治疗一直是一个医学挑战，在过去几十年中，总体生存率的提高有限。然而，最近，免疫疗法领域的一些非常有趣的创新已经被证明对晚期 HNSCC 患者有益。本文综述了最新的医学进展，特别关注免疫疗法领域的临床成就和当前的临床研究。临床研究的格局已经发生了很大的变化，从基于抗体的生长因子抑制转向免疫检查点调节，新的辅助和新辅助治疗的适应证正在大量患者群体中进行测试。甚至两种或更多免疫调节方法的联合应用以及与标准癌症治疗的正确同步也很有前景，值得进行适当的临床试验。
